Wish, Jay B.Eckardt, Kai-UweKovesdy, Csaba P.Fishbane, StevenSpinowitz, Bruce S.Berns, Jeffrey S.2023-02-232023-02-232021-11Wish, J. B., Eckardt, K.-U., Kovesdy, C. P., Fishbane, S., Spinowitz, B. S., & Berns, J. S. (2021). Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 78(5), 709–718. https://doi.org/10.1053/j.ajkd.2021.06.019https://hdl.handle.net/1805/31441The National Kidney Foundation convened an interdisciplinary international workshop in March 2019 to discuss the potential role of a new class of agents for the treatment of anemia in patients with chronic kidney disease (CKD): the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). International experts with expertise in physiology, biochemistry, structural chemistry, translational medicine, and clinical management of anemia participated. Participants reviewed the unmet needs of current anemia treatment, the biology of hypoxia-inducible factor, the pharmacology of prolyl hydroxylase inhibitors, and the results of phase 2 clinical trials of HIF-PHIs among patients with CKD, both those treated by dialysis and those not receiving kidney replacement therapy. The results of key phase 3 clinical trials of HIF-PHIs available as of the time of writing are also included in this report, although they appeared after the workshop was completed. Participants in the workshop developed a number of recommendations for further examination of HIF-PHIs, which are summarized in this report and include long-term safety issues, potential benefits, and practical considerations for implementation including patient and provider education.enPublisher Policyanemiachronic kidney diseasehypoxia inducible factorArticle